CDK4/6 inhibitors (CDK4/6i), including abemaciclib, palbociclib and ribociclib, in combination with hormone therapy have been used to treat hormone receptor-positive (HR+), HER2-negative metastatic BC [127–129]. This evidence concerns the gene ERBB2 and breast cancer.